Cardiovascular Diseases

Failure of Phase II cannabidiol trial leads to loss for Zynerba Zynerba Pharmaceuticals’ phase II trial for transdermal cannabinoid candidate missed all its endpoints, as it failed to hit a single goal or show a dose response raises big doubts about the drug's prospects. This news eroded around 55% off Zynerba’s stock price. 188 enrolled adults with refractory epilepsy with focal seizures were randomized to receive one of two doses of ZYN002 or placebo. Zynerba hoped to show its cannabidiol gel cut focal seizures but ultimately it fell short of that goal. Participants who received the low dose of ZYN002 experienced an 18.4% median reduction in focal seizures. The figur...